{"id":"placebo-anti-h1","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-H1 antihistamines competitively antagonize histamine at H1 receptors, which are responsible for allergic symptoms such as itching, urticaria, and angioedema. The placebo component serves as a control in this phase 3 trial design. Together, this combination is used to evaluate the efficacy of anti-H1 therapy in allergic conditions.","oneSentence":"Placebo combined with an anti-H1 antihistamine blocks histamine H1 receptors to reduce allergic and inflammatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:18.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic conditions (specific indication not detailed in provided information)"}]},"trialDetails":[{"nctId":"NCT06042478","phase":"PHASE3","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-15","conditions":"Chronic Spontaneous Urticaria","enrollment":470},{"nctId":"NCT06228560","phase":"PHASE2","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Longbio Pharma","startDate":"2024-01-26","conditions":"Chronic Spontaneous Urticaria","enrollment":202},{"nctId":"NCT04976192","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2021-08-30","conditions":"Chronic Urticaria","enrollment":608},{"nctId":"NCT05774639","phase":"PHASE3","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2023-08-15","conditions":"Chronic Idiopathic Urticaria","enrollment":600},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT05024058","phase":"PHASE3","title":"Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-16","conditions":"Chronic Inducible Urticaria","enrollment":39},{"nctId":"NCT03749148","phase":"PHASE2","title":"Cholinergic Urticaria - Efficacy of Dupilumab","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-12-10","conditions":"Cholinergic Urticaria","enrollment":48},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT00359138","phase":"PHASE4","title":"The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypersensitivity","enrollment":36},{"nctId":"NCT03749135","phase":"PHASE2","title":"Dupilumab in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-12","conditions":"Chronic Spontaneous Urticaria, Recurrent Angioedema","enrollment":72},{"nctId":"NCT01723072","phase":"PHASE3","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-23","conditions":"Chronic Spontaneous Urticaria, Angioedema","enrollment":91},{"nctId":"NCT02452463","phase":"PHASE2","title":"Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2015-06-29","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":8},{"nctId":"NCT03183024","phase":"PHASE4","title":"Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody","status":"COMPLETED","sponsor":"Jonathan A. Bernstein, MD","startDate":"2017-09-12","conditions":"Chronic Idiopathic Urticaria","enrollment":12},{"nctId":"NCT02814630","phase":"NA","title":"Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Asthma Inc Clinical Research Center","startDate":"2016-09","conditions":"Chronic Idiopathic Urticaria","enrollment":20},{"nctId":"NCT01960283","phase":"PHASE3","title":"Methotrexate in the Treatment of Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-11","conditions":"Chronic Urticaria","enrollment":83},{"nctId":"NCT00605852","phase":"PHASE1","title":"Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-29","conditions":"Rhinitis, Allergic, Seasonal","enrollment":29},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT02329223","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12","conditions":"Chronic Spontaneous Uriticaria","enrollment":218},{"nctId":"NCT01599637","phase":"PHASE2","title":"Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Idiopathic Urticaria","enrollment":40},{"nctId":"NCT00150761","phase":"PHASE4","title":"Facial Thermography Study of Levocetirizine Versus Cetirizine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-07","conditions":"Anti-allergic Agents","enrollment":60},{"nctId":"NCT01287117","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":319},{"nctId":"NCT01264939","phase":"PHASE3","title":"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-02","conditions":"Chronic Idiopathic Urticaria","enrollment":336},{"nctId":"NCT01292473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-03","conditions":"Chronic Idiopathic Urticaria","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo of methetrexate + anti-H1"],"phase":"phase_3","status":"active","brandName":"Placebo + anti-H1","genericName":"Placebo + anti-H1","companyName":"University Hospital, Tours","companyId":"university-hospital-tours","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo combined with an anti-H1 antihistamine blocks histamine H1 receptors to reduce allergic and inflammatory responses. Used for Allergic conditions (specific indication not detailed in provided information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}